All In Biotech

Drug Trial Radar · NCT00330148

Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis

Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase

Last checked: Nov 20, 2026Latest source record: May 26, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 435 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

435

Actual

Start

Mar 2001

Primary completion

Not stated

Study completion Jun 2004

Sponsor

Lead sponsor
EpicentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Médecins Sans Frontières, France; Embassy of France in Uganda; National Sleeping Sickness Control Program, Uganda
First posted
May 26, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The treatment human African trypanosomiasis (HAT) in the meningoencephalitic phase relies on two molecules officially registered: melarsoprol, the most commonly used, has a poor safety profile and is becoming ineffective due to parasite resistance; and eflornithine, with better tolerance but more complicated and expensive to implement in endemic countries. nifurtimox, registered only for Chagas' disease but used off-label since the 1970's in series of cases of HAT, is at present the only other available alternative. The very limited number of compounds available, the lack of prospects for the development of new products and the emergence of resistance are arguments for the use of therapeutic combinations. This study evaluates the efficacy and safety of three drug combination therapies: melarsoprol-nifurtimox, melarsoprol-eflornithine and eflornithine-nifurtimox.

Conditions

  • Trypanosomiasis, African

Interventions

  • melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10dDrug

  • melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7dDrug

  • nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7dDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cure rate

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Omugo Sleeping Sickness Treatment Center

    Omugo, Arua District, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.